Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Rhythm Pharmaceuticals, LG Chem expand bivamelagon obesity license deal to $855M from $305M
Licensing deal, obesity, small molecule, milestone payments, royalties - Read more

Lonza acquires five Merck KGaA US manufacturing facilities for mid-triple-digit millions CHF, boosting ADC capabilities
Acquisition, manufacturing, antibody-drug conjugate, viral vector, bioconjugation - Read more

Aarvik Therapeutics, Laurus Labs license two MUTTA ADC molecules for development and commercialization in India
Licensing deal, research collaboration, oncology, antibody-drug conjugate, milestone payments - Read more

Basilea Pharmaceutica, Pfizer strong Cresemba European sales trigger $37.5M milestone payment
Licensing deal, infectious disease, small molecule, milestone payments, royalties - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Pfizer raises 2026 annual revenue guidance to $62B–$64B on strong commercial performance and cost cuts
Financial performance, oncology, cost reduction, strategic - Read more

Kyowa Kirin reports 58.5% profit surge in nine-month FY26 results, reiterates full-year outlook
Biopharmaceutical, rare disease, financial, revenue impact - Read more

Bayer pharma unit hits "turning point" with 8% Q3 sales growth, raises full-year outlook
Small molecule, cardiovascular, oncology, revenue impact - Read more

Specific Biologics raises $35M Series A, expanding precision gene-editing platform for genetic diseases
Gene therapy, rare disease, CRISPR, AAV, preclinical - Read more

Vertex Pharmaceuticals secures MHRA approval expanding Casgevy access to children aged 5+ in UK
Gene therapy, rare disease, reimbursement, pediatric access - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Novartis terminates BioArctic neurodegeneration and brain-delivery alliance worth up to $772M
Termination, neurological, antibody, licensing deal, blood-brain barrier technology - Read more

AbbVie discontinues (livmoniplimab) Ph2 program in solid tumors due to limited benefit over standard of care
Antibody, cancer, monoclonal antibody, non-small cell lung cancer, TGF-β1, PD-1 inhibitor - Read more

Philips sets aside $322M provision for proposed DOJ settlement over Respironics sleep apnea recall
Medical device, sleep disorders, financial, major transaction - Read more

Sun Pharma halts eye-care drug production at Indian plant amid regulators' quality management failures
Ophthalmic drugs, ophthalmology, operational, regulatory - Read more

FDA issues Form 483 write-ups to Hansoh Pharma and Samsung Biologics over manufacturing concerns
Manufacturing, biologics, operational, regulatory - Read more

Pfizer cuts obesity and lung disease candidates, dropping multiple phase 1 and 2 pipeline programs
Small molecule, cardiovascular, oncology, pipeline reduction, strategic - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here